Pharmaceuticals, Biotechnology and Life Sciences
– Presentation to be webcast on www.exelixis.com – ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey,…
Completed enrollment of an ongoing non-IND clinical study of AXA1125/AXA1957 in more than 100 adult subjects with NAFLD Announced intent…
– Clinical programs on track for multiple topline data releases in 2020 – – Entered clinical trial collaboration with Merck…
New Data from Phase I/IIa Clinical Study of OpRegen® Presented at 2019 AAO Meeting; All Cohort 4 Patients Have Better…
— Lead investigational medicine COR388, a potentially transformative new paradigm for addressing Alzheimer’s disease, continues to advance in Phase 2/3…
–SYNB1618 solid oral bridging study ongoing and SYNB1891 immuno-oncology study open – – Company ends 3Q2019 with approximately $139 million…
Conference Call Today at 4:30 p.m. ET SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing…
XERAVA™ Carton Sales Grew over 30% Compared with Second Quarter of 2019 Increased Formulary Uptake, with a 99% Success Rate…
Chairman and Chief Executive Officer Paul Tufano to accept award during inaugural Diversity & Inclusion Awards Gala PHILADELPHIA–(BUSINESS WIRE)–#AmeriHealthCaritas—AmeriHealth Caritas,…
OAKLAND, Calif.–(BUSINESS WIRE)–#CWCI–The prevalence of opioids in California workers’ comp lost-time claims has dropped 51% over the past decade, reducing…